An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors

AB248 - Asher Biotherap

Keytruda (pembrolizumab) - Merck (MSD)

https://www.abstractsonline.com/pp8/#!/10828/presentation/10446

Elizabeth I. Buchbinder; David R. Spigel; Costantine Albany; Michael Chisamore; Kelly D. Moynihan; Xiaohan Liu; Christopher DelNagro; Matt Axt; Andrea Pirzkall

Mar 14, 2023